Mithramycin, an agent for developing new therapeutic drugs for neurodegenerative diseases

Journal of Pharmacological Sciences

Volumn 122, Issue 4, 2013, Pages 251-256

  Osada, Nobuhiro ^a   Kosuge, Yasuhiro ^a   Ishige, Kumiko ^a   Ito, Yoshihisa ^a  

^a NIHON UNIVERSITY   (Japan)

Author keywords

Endoplasmic reticulum stress; Mithramycin; Neurodegenerative disease; Neuroprotective effect; Specificity protein 1 (Sp1)

Indexed keywords

DOPAMINE; METHAMPHETAMINE; MITHRAMYCIN; MITHRAMYCIN A; MITHRAMYCIN A SDK; MITHRAMYCIN A SK; UNCLASSIFIED DRUG;

DEGENERATIVE DISEASE; DRUG MECHANISM; ENDOPLASMIC RETICULUM STRESS; HUMAN; HUNTINGTON CHOREA; LIVER TOXICITY; LONG TERM POTENTIATION; NEPHROTOXICITY; NERVE CELL NECROSIS; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; REPERFUSION INJURY; REVIEW; SINGLE DRUG DOSE;

ANIMALS; CELL DEATH; CELLS, CULTURED; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; ENDOPLASMIC RETICULUM STRESS; HIPPOCAMPUS; HUMANS; HUNTINGTON DISEASE; LONG-TERM POTENTIATION; METHAMPHETAMINE; MICE; MOLECULAR TARGETED THERAPY; NEURODEGENERATIVE DISEASES; NEURONS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PLICAMYCIN; REPERFUSION INJURY;

EID: 84883313329     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.13R02CP     Document Type: Review

References (33)

1. Kennedy BJ, Yarbro JW, Kickertz V, Sandberg-Wollheim M. Effect of mithramycin on a mouse glioma. Cancer Res. 1968; 28:91-97.
2. Ream NW, Perlia CP, Wolter J, Taylor SG 3rd. Mithramycin therapy in disseminated germinal testicular cancer. JAMA. 1968;204:1030-1036.
3. Snyder RC, Ray R, Blume S, Miller DM. Mithramycin blocks transcriptional initiation of the c-myc P1 and P2 promoters. Biochemistry. 1991;30:4290-4297.
4. Lee TJ, Jung EM, Lee JT, Kim S, Park JW, Choi KS, et al. Mithramycin A sensitizes cancer cells to TRAIL-mediated apoptosis by down-regulation of XIAP gene promoter through Sp1 sites. Mol Cancer Ther. 2006;11:2737-2746. (Pubitemid 44849000)
5. Taylor DJ, Parsons CE, Han H, Jayaraman A, Rege K. Parallel screening of FDA-approved antineoplastic drugs for identifying sensitizers of TRAIL-induced apoptosis in cancer cells. BMC Cancer. 2011;11:470.
6. Grohar PJ, Woldemichael GM, Griffin LB, Mendoza A, Chen QR, Yeung C, et al. Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening. J Natl Cancer Inst. 2011;103:962-978.
7. Chatterjee S, Zaman K, Ryu H, Conforto A, Ratan RR. Sequence-selective DNA binding drugs mithramycin A and chromomycin A3 are potent inhibitors of neuronal apoptosis induced by oxidative stress and DNA damage in cortical neurons. Ann Neurol. 2001;49:345-354. (Pubitemid 32202788)
8. Vidal R, Caballero B, Couve A, Hetz C. Converging pathways in the occurrence of endoplasmic reticulum (ER) stress in Huntington's disease. Curr Mol Med. 2011;11:1-12.
9. Gil JM, Rego AC. The R6 lines of transgenic mice: a model for screening new therapies for Huntington's disease. Brain Res Rev. 2009;59:410-431.
10. Ferrante RJ, Ryu H, Kubilus JK, D'Mello S, Sugars KL, Lee J, et al. Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease. J Neurosci. 2004;24:10335-10342. (Pubitemid 39552617)
11. Coles R, Caswell R, Rubinsztein DC. Functional analysis of the Huntington's disease (HD) gene promoter. Hum Mol Genet. 1998;7:791-800. (Pubitemid 28221241)
12. Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, Anthony RM, et al. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nature Med. 1996;2: 699-703. (Pubitemid 26191961)
13. Jang EY, Park KA, Lee JR, Yang CH, Hwang M. Protective effect of sauchinone on methamphetamine-induced neurotoxicity in mice. J Pharmacol Sci. 2012;118:531-536.
14. Jiang Y, Langley B, Lubin FD, Renthal W, Wood MA, Yasui DH, et al. Epigenetics in the nervous system. J Neurosci. 2008; 28:11753-11759.
15. Akbarian S, Huang HS. Epigenetic regulation in human brainfocus on histone lysine methylation. Biol Psychiatry. 2009;65:198-203.
16. Hagiwara H, Iyo M, Hashimoto K. Mithramycin protects against dopaminergic neurotoxicity in the mouse brain after administration of methamphetamine. Brain Res. 2009;1301:189-196.
17. Jayanthi S, Deng X, Noailles PA, Ladenheim B, Cadet JL. Methamphetamine induces neuronal apoptosis via cross-talks between endoplasmic reticulum and mitochondria-dependent death cascades. FASEB J. 2004;18:238-251. (Pubitemid 38186243)
18. Paschen W, Mengesdorf T. Cellular abnormalities linked to endoplasmic reticulum dysfunction in cerebrovascular disease - therapeutic potential. Pharmacol Ther. 2005;108:362-375. (Pubitemid 41693766)
19. Gorman AM, Healy SJ, Jager R, Samali A. Stress management at the ER: regulators of ER stress-induced apoptosis. Pharmacol Ther. 2012;134:306-316.
20. Kosuge Y, Taniguchi Y, Imai T, Ishige K, Ito Y. Neuroprotective effect of mithramycin against endoplasmic reticulum stress- induced neurotoxicity in organotypic hippocampal slice cultures. Neuropharmacology. 2011;61:252-261.
21. Concannon CG, Ward MW, Bonner HP, Kuroki K, Tuffy LP, Bonner CT, et al. NMDA receptor-mediated excitotoxic neuronal apoptosis in vitro and in vivo occurs in an ER stress and PUMA independent manner. J Neurochem. 2008;105:891-903. (Pubitemid 351565712)
22. Davis SM, Lees KR, Albers GW, Diener HC, Markabi S, Karlsson G, et al. Selfotel in acute ischemic stroke: possible neurotoxic effects of an NMDA antagonist. Stroke. 2000;31: 347-354. (Pubitemid 30078164)
23. Ginsberg MD. Neuroprotection for ischemic stroke: past, present and future. Neuropharmacology. 2008;55:363-389.
24. Osada N, Kosuge Y, Ishige K, Ito Y. Characterization of neuronal and astroglial responses to ER stress in the hippocampal CA1 area in mice following transient forebrain ischemia. Neurochem Int. 2010;57:1-7.
25. Osada N, Kosuge Y, Oguchi S, Miyagishi H, Ishige K, Ito Y. Protective action of mithramycin against neurodegeneration and impairment of synaptic plasticity in the hippocampal CA1 area after transient global ischemia. Neurochem Int. 2012;60:47-54.
26. Ting J, Lee AS. Human gene encoding the 78,000-dalton glucose-regulated protein and its pseudogene: structure, conservation, and regulation. DNA. 1988;7:275-286.
27. Park JS, Luethy JD, Wang MG, Fargnoli J, Fornace AJ Jr, McBride OW, et al. Isolation, characterization and chromosomal localization of the human GADD153 gene. Gene. 1992;116:259-267.
28. Takasaki K, Uchida K, Fujikawa R, Nogami A, Nakamura K, Kawasaki C, et al. Neuroprotective effects of citidine-5- diphosphocholine on impaired spatial memory in a rat model of cerebrovascular dementia. J Pharmacol Sci. 2011;116:232-237.
29. Volpe BT, Petito CK. Dementia with bilateral medial temporal lobe ischemia. Neurology. 1985;35:1793-1797. (Pubitemid 16222771)
30. Albertini V, Jain A, Vignati S, Napoli S, Rinaldi A, Kwee I, et al. Novel GC-rich DNA-binding compound produced by a genetically engineered mutant of the mithramycin producer Streptomyces argillaceus exhibits improved transcriptional repressor activity: implications for cancer therapy. Nucleic Acids Res. 2006;34:1721-1734.
31. Previdi S, Malek A, Albertini V, Riva C, Capella C, Broggini M, et al. Inhibition of Sp1-dependent transcription and antitumor activity of the new aureolic acid analogues mithramycin SDK and SK in human ovarian cancer xenografts. Gynecol Oncol. 2010;118:182-188.
32. Sleiman SF, Langley BC, Basso M, Berlin J, Xia L, Payappilly JB, et al. Mithramycin is a gene-selective Sp1 inhibitor that identifies a biological intersection between cancer and neurodegeneration. J Neurosci. 2011;31:6858-6870.
33. Lajoie P, Snapp EL. Changes in BiP availability reveal hypersensitivity to acute endoplasmic reticulum stress in cells expressing mutant huntingtin. J Cell Sci. 2011;124:3332-3343.